Hong Kong Food Stock News

SEHK:1316
SEHK:1316Auto Components

Nexteer Automotive Group (SEHK:1316) Margin Recovery Reinforces Bullish Earnings Narratives

Nexteer Automotive Group (SEHK:1316) opened FY 2025 with first half revenue of about US$2.2b and basic EPS of roughly US$0.03, against trailing twelve month figures showing basic EPS of about US$0.04 on revenue of roughly US$4.6b and earnings growth of 65.3% over the past year. Over the last three reported half year periods, revenue has moved from about US$2.1b in 1H FY 2024 to US$2.2b in 1H FY 2025, while basic EPS has shifted from roughly US$0.01 to about US$0.03 as net margins increased...
SEHK:2487
SEHK:2487Biotechs

Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative

Cutia Therapeutics (SEHK:2487) opened FY 2025 with first half revenue of C¥66.3 million and a basic EPS loss of C¥0.75, while trailing twelve month revenue sat at C¥336.2 million against a basic EPS loss of C¥1.03. The company reported revenue of C¥95.6 million in the first half of 2024, C¥184.0 million in the second half of 2024, and C¥66.3 million in the first half of 2025, with basic EPS losses of C¥0.66, C¥0.75 and C¥0.75 over those same periods. This sequence highlights that investors...
SEHK:1675
SEHK:1675Software

AsiaInfo Technologies (SEHK:1675) Margin Squeeze Deepens As EPS Loss Tests Bullish Growth Narrative

AsiaInfo Technologies (SEHK:1675) has opened FY 2025 with first half revenue of C¥2.6b and a basic EPS loss of C¥0.22, setting a cautious tone for investors watching how the recent slowdown in profitability plays through the rest of the year. The company has seen first half revenue move from C¥3.0b in 2024, when EPS was a loss of C¥0.06, to C¥2.6b in 2025 alongside a trailing twelve month EPS of C¥0.13, leaving the latest results framed by thin margins and plenty of focus on how quickly...
SEHK:1702
SEHK:1702Chemicals

Dongguang Chemical (SEHK:1702) Margin Rebound To 5.9% Challenges Bearish Profitability Narrative

Dongguang Chemical (SEHK:1702) has posted its FY 2025 results with first half revenue of CNY 1.2b and basic EPS of CNY 0.12, while trailing twelve month revenue came in at CNY 2.4b with basic EPS of CNY 0.23, set against a 65.5% earnings rise and a net profit margin of 5.9% for the period. Over recent periods the company has seen revenue move from CNY 1.34b in 2024 H1 to CNY 1.24b in 2024 H2 and CNY 1.18b in 2025 H1. Basic EPS shifted from CNY 0.15 in 2024 H1 to a small loss in 2024 H2 and...
SEHK:210
SEHK:210Luxury

Daphne International Holdings (SEHK:210) Earnings Growth Slows And Tests Bullish Narratives

Daphne International Holdings (SEHK:210) has reported its FY 2025 first half results with revenue of C¥198.3 million, basic EPS of C¥0.0327 and trailing 12 month earnings growth of 9.4% year over year. Over recent periods, the company has seen revenue move from C¥153.5 million in 2H 2024 to C¥198.3 million in 1H 2025, while trailing 12 month basic EPS has progressed from C¥0.0539 to C¥0.059. This sets the scene for investors to weigh these earnings against a 32.1% net profit margin that...
SEHK:902
SEHK:902Renewable Energy

Huaneng Power International (SEHK:902) Margin Improvement Challenges Cautious Earnings Narratives

Huaneng Power International (SEHK:902) has wrapped up FY 2025 with fourth quarter revenue of C¥56.3b and basic EPS of C¥0.02 loss, against a backdrop of trailing twelve month EPS of C¥0.74 on revenue of C¥229.3b and a 99.8% year over year lift in earnings and net margin moving from 2.9% to 6.3%. Over recent periods, the company has seen quarterly revenue move from C¥61.2b in Q4 2024 to C¥60.9b in Q3 2025 and C¥56.3b in Q4 2025. Basic EPS shifted from a C¥0.83 loss in Q4 2024 to C¥0.30 in Q3...
SEHK:867
SEHK:867Pharmaceuticals

China Medical System Holdings (SEHK:867) Valuation After Desidustat Approval And Recent Share Price Pullback

China Medical System Holdings (SEHK:867) has secured Chinese regulatory approval for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis adult chronic kidney disease patients, expanding its presence in the nephrology segment. See our latest analysis for China Medical System Holdings. The share price is at HK$13.27 after a 1 day share price return of 2.47%. However, the 30 day share price return shows a 14.05% decline, which contrasts with an 82.01% 1 year total shareholder...
SEHK:212
SEHK:212Real Estate

Nanyang Holdings (SEHK:212) Returns To Profitability Challenging Bearish Earnings Narratives

Nanyang Holdings (SEHK:212) has posted its FY 2025 first half numbers with revenue of HK$194.4 million and basic EPS of HK$0.81, a clear contrast to the losses seen across the trailing twelve months where basic EPS came to a loss of HK$1.47 on revenue of HK$253.2 million. Over recent periods, the company has seen revenue move between HK$144.8 million and HK$251.3 million per half year, while basic EPS swung from losses of HK$4.32 and HK$3.03 per share to the latest positive HK$0.81 print...
SEHK:2342
SEHK:2342Communications

Comba Telecom Systems Holdings (SEHK:2342) Returns To Profit In 1H 2025 Challenging Bearish Narratives

Latest FY 2025 Earnings Snapshot Comba Telecom Systems Holdings (SEHK:2342) has just posted its FY 2025 first half numbers, with revenue of HK$2,199.2 million and net income of HK$61.8 million, translating into basic EPS of HK$0.021. Looking back over the last three reported half year periods, revenue moved from HK$2,343.5 million in 1H 2024 to HK$2,184.8 million in 2H 2024 and now HK$2,199.2 million in 1H 2025. Net income shifted from a loss of HK$158.4 million and then HK$405.8 million in...
SEHK:20
SEHK:20Software

SenseTime Group (SEHK:20) Loss Narrowing In 2H FY 2025 Tests Growth Heavy Bull Case

SenseTime Group (SEHK:20) just posted its FY 2025 second half scorecard, with revenue of C¥2.7b and a basic EPS loss of C¥0.01, while trailing 12 month figures show revenue of C¥5.0b and a basic EPS loss of C¥0.05. Over the past few reporting halves, the company has seen revenue move from C¥2.0b in 2H 2024 to C¥2.4b in 1H 2025 and then C¥2.7b in 2H 2025. Basic EPS losses shifted from C¥0.05 in 2H 2024 to C¥0.04 in 1H 2025 and C¥0.01 in 2H 2025, putting revenue scale and loss levels front and...
SEHK:728
SEHK:728Telecom

China Telecom (SEHK:728) Margin Stability Tests Bullish Profit Expansion Narrative

China Telecom (SEHK:728) has wrapped up FY 2025 with fourth quarter revenue of C¥129.7b and basic EPS of C¥0.024811, while trailing twelve month revenue came in at C¥523.9b with EPS of C¥0.36, giving investors a clear view of both the latest quarter and the broader run rate. In recent periods, the company has seen quarterly revenue range from C¥124.8b to C¥135.5b and basic EPS move between C¥0.081679 and C¥0.154665, with trailing twelve month EPS holding in a narrow band around the mid...
SEHK:2233
SEHK:2233Basic Materials

West China Cement (SEHK:2233) Net Margin Improvement Challenges Bearish Debt Coverage Concerns

West China Cement FY 2025 earnings snapshot West China Cement (SEHK:2233) has put fresh numbers on the table for FY 2025, with first half revenue at C¥5.4b and basic EPS of C¥0.14, while the trailing twelve months show revenue of C¥10.1b and EPS of C¥0.16 against a share price of HK$2.22. The company has seen revenue move from C¥4.6b and EPS of C¥0.04 in the second half of 2024 to C¥5.4b and EPS of C¥0.14 in the first half of 2025, setting up a story where profit margins and earnings quality...
SEHK:1848
SEHK:1848Trade Distributors

China Aircraft Leasing Group Holdings (SEHK:1848) Earnings Rebound Tests Cash Flow Concerns

Financial results snapshot China Aircraft Leasing Group Holdings (SEHK:1848) has reported its FY 2025 first half results with revenue of HK$917.7 million and basic EPS of HK$0.189. This sits against prior halves where revenue was HK$1,040.6 million in 1H 2024 and HK$939.7 million in 2H 2024, alongside EPS of HK$0.177 and HK$0.169 respectively. Over the trailing twelve months, revenue was HK$2.8 billion with basic EPS of HK$0.454 and net income of HK$338.5 million. Together, these figures give...
SEHK:780
SEHK:780Hospitality

Tongcheng Travel (SEHK:780) Q4 Margin Volatility Tests Bullish High‑Quality Earnings Narrative

Tongcheng Travel Holdings (SEHK:780) has wrapped up FY 2025 with fourth quarter revenue of C¥4.8b and basic EPS of C¥0.04, while trailing twelve month revenue stood at C¥19.4b and EPS at C¥1.03. The company has seen revenue move from C¥17.3b to C¥19.4b over the past year on a trailing basis, with EPS rising from C¥0.87 to C¥1.03. Earnings growth was 20.1% over the same period. With trailing net margin at 12.2% and described as supported by high quality earnings, the latest results put...
SEHK:563
SEHK:563Real Estate

Shanghai Industrial Urban Development Group (SEHK:563) Loss Worsens And Reinforces Bearish Earnings Narratives

Shanghai Industrial Urban Development Group (SEHK:563) has reported FY 2025 first half revenue of HK$1,827.8 million, with a basic EPS loss of HK$0.10. This puts the focus firmly on how efficiently that top line is translating into bottom line results. Over the past year of reported periods, revenue has ranged from HK$2,980.8 million in 1H 2024 to HK$9,459.5 million in 2H 2024. Over the same intervals, basic EPS has moved between a loss of HK$0.02 and a loss of HK$0.10, giving investors a...
SEHK:135
SEHK:135Gas Utilities

Kunlun Energy (SEHK:135) Margin Compression Challenges Bullish Narratives After FY 2025 Results

Kunlun Energy FY 2025 earnings snapshot Kunlun Energy (SEHK:135) has reported fresh numbers for FY 2025, with first half revenue of C¥97.5b and basic EPS of C¥0.37. The company’s revenue moved from C¥94.1b and EPS of C¥0.31 in 2H 2024 to C¥97.5b and C¥0.37 in 1H 2025. Trailing twelve month EPS is C¥0.62 on revenue of C¥195.8b, leaving investors weighing a modest earnings profile against margins that remain relatively thin. See our full analysis for Kunlun Energy. With the headline figures...
SEHK:1810
SEHK:1810Tech

Xiaomi (SEHK:1810) Q4 EPS Slowdown Tests Bullish Margin Expansion Narrative

Fresh off its FY 2025 results, Xiaomi (SEHK:1810) reported fourth quarter revenue of about CN¥116.9b and basic EPS of CN¥0.25, setting the tone for a year where trailing 12 month revenue reached roughly CN¥457.3b and basic EPS came in at CN¥1.62. Over that period, net income excluding extra items totaled about CN¥41.6b, giving investors a clear read on how headline earnings are translating into underlying profitability and where margins are holding up through the latest quarter. See our full...
SEHK:2591
SEHK:2591Biotechs

Guangzhou Innogen Pharmaceutical Group (SEHK:2591) Heavy Losses Challenge High Growth Narratives

Guangzhou Innogen Pharmaceutical Group (SEHK:2591) has reported its FY 2025 first half with revenue of C¥56.4 million, a basic EPS loss of C¥0.29 and net income loss of C¥122.47 million, while trailing twelve month figures show revenue of C¥131.5 million, a basic EPS loss of C¥0.79 and net income loss of C¥341.36 million. The company has seen first half revenue move from C¥0 in FY 2024 to C¥56.4 million in FY 2025 as EPS moved from a basic loss of C¥0.18 to a loss of C¥0.29. This sets up a...
SEHK:2111
SEHK:2111Luxury

Best Pacific International Holdings (SEHK:2111) Margin Drift Challenges Bullish EPS Growth Narrative

Best Pacific International Holdings (SEHK:2111) has posted its FY 2025 first half results with revenue of HK$2,329.8 million and basic EPS of HK$0.25, setting the tone against a backdrop of forecast earnings growth of about 18.6% per year and revenue growth of roughly 8.8% per year. The company has seen revenue move from HK$2,385.4 million in 1H 2024 to HK$2,675.9 million in 2H 2024 and then to HK$2,329.8 million in 1H 2025, while EPS has shifted from HK$0.27 to HK$0.32 and now HK$0.25. This...
SEHK:2269
SEHK:2269Life Sciences

WuXi Biologics (SEHK:2269) Margin Improvement Challenges Bearish Profitability Narratives

WuXi Biologics (Cayman) (SEHK:2269) has reported its FY 2025 numbers with second half revenue of about C¥11.8b and basic EPS of C¥0.64, supported by trailing twelve month revenue of roughly C¥21.8b and EPS of C¥1.22 that sit alongside a 46.3% year over year earnings gain. The company has seen revenue move from around C¥18.7b to C¥21.8b on a trailing basis, while trailing EPS has shifted from C¥0.82 to C¥1.22, setting up a story where rising profit levels are paired with healthier margins that...
SEHK:2097
SEHK:2097Hospitality

Mixue Group (SEHK:2097) Earnings Growth Of 32.7% Tests High P/E Valuation Concerns

MIXUE Group (SEHK:2097) FY 2025 earnings snapshot MIXUE Group (SEHK:2097) has reported FY 2025 results with second half revenue of C¥18.7b and basic EPS of C¥2.82, alongside trailing 12 month revenue of C¥33.6b and EPS of C¥7.83, giving investors a fresh look at how the business is scaling. The company has seen revenue move from C¥10.7b and EPS of C¥5.23 in the first half of 2024 to C¥14.9b and EPS of C¥7.23 in the first half of 2025, with trailing 12 month revenue stepping up from C¥24.8b...
SEHK:1833
SEHK:1833Consumer Retailing

Ping An Healthcare And Technology (SEHK:1833) Profitability Milestone Tests Bullish Narratives

Ping An Healthcare and Technology (SEHK:1833) has just posted its FY 2025 first half numbers, with revenue at C¥2.5b and basic EPS of C¥0.07, alongside net income of C¥134.2m that builds on its recent move into profitability. Over the recent reporting periods, revenue has shifted from C¥2.1b in 1H 2024 to C¥2.7b in 2H 2024 and C¥2.5b in 1H 2025, while basic EPS has moved from C¥0.05 in 1H 2024 to C¥0.02 in 2H 2024 and C¥0.07 in 1H 2025. This sets up a results story where investors will be...
SEHK:316
SEHK:316Shipping

Orient Overseas (International) (SEHK:316) Valuation After Lower 2025 Earnings And Proposed Final Dividend

Orient Overseas (International) (SEHK:316) shares were in focus after the company reported full year 2025 results showing lower sales and net income, alongside a proposed final dividend of US$0.42 per share payable in multiple currencies. See our latest analysis for Orient Overseas (International). The latest earnings update, which includes lower sales and net income alongside a proposed US$0.42 dividend, comes as the share price sits at HK$144.2 with a 90 day share price return of 16.1%. The...
SEHK:1910
SEHK:1910Luxury

Assessing Samsonite Group (SEHK:1910) Valuation After Earnings Declines Leadership Change Dividend Plan And US Dual Listing Move

What the latest results and board changes mean for Samsonite Group Samsonite Group (SEHK:1910) just packed several developments into one update, combining full year 2025 earnings, a proposed US$140 million dividend, a planned chairmanship handover and shareholder approval to prepare for a potential US dual listing. See our latest analysis for Samsonite Group. Those announcements landed after a tough stretch for the stock, with a 30 day share price return of 23.03% decline and a year to date...